Back to Journals » Infection and Drug Resistance » Volume 12

In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae

Authors Hipp M, Burckhardt I

Received 24 January 2019

Accepted for publication 24 April 2019

Published 1 July 2019 Volume 2019:12 Pages 1889—1893

DOI https://doi.org/10.2147/IDR.S202789

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Sahil Khanna


Marlene Hipp, Irene Burckhardt

Department for Infectious Diseases, Microbiology and Hygiene, University Hospital of Heidelberg, Heidelberg, Germany

Background: Since the first isolation of Streptococcus pneumoniae with low penicillin susceptibility in the 1960s, resistant strains have spread over the globe, causing substantial problems in the treatment of pneumococcal infections. However, in Germany, rates of non-susceptibility are still below 5%.
Methods: Since 2009 clinical pneumococcal strains have been collected at the Center for Infectious Diseases, Heidelberg University Hospital, Germany. In this study, 56 of these strains were chosen due to their decreased penicillin susceptibility (minimal inhibitory concentration (MIC)≥0.12 μg/mL). Sixteen of these strains even showed an MIC of ≥2 μg/mL. We examined the in vitro activity of newer antimicrobials known to be active against Gram-positive bacteria. For this purpose MICs of ceftaroline, ceftobiprole, dalbavancin, delafloxacin, eravacycline, tedizolid, and telavancin were determined and evaluated.
Results: All of the 7 antimicrobial agents inhibited pneumococcal growth at concentrations of 0.5 μg/mL or lower. Currently, clinical breakpoints are only available for two substances, ceftaroline and ceftobiprole. According to these breakpoints, all MICs were below the susceptibility breakpoint; however, there was a correlation between high penicillin MICs (≥2 μg/mL) and MICs near the ceftaroline and ceftobiprole susceptibility breakpoint. The other agents showed very promising effects against all tested strains with the lowest MIC90 of 0.002 μg/mL for telavancin.
Conclusion: Consequently, this study demonstrates the promising in vitro activity of newer antimicrobials against penicillin non-susceptible strains of S. pneumoniae.

Keywords: Streptococcus pneumoniae, penicillin resistance, susceptibility testing
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]